eCite Digital Repository
A clinical audit of kidney transplant recipients with antibody mediated rejection in Southern Tasmania
Citation
Patel, Bansari and Nejatian, A and Skeat, L and Kirkland, G and Jose, M, A clinical audit of kidney transplant recipients with antibody mediated rejection in Southern Tasmania, pp. 79-79. ISSN 1320-5358 (2020) [Conference Extract]
 | PDF (Abstract) Pending copyright assessment - Request a copy 48Kb |
Abstract
Aim: To review the diagnosis, management and outcomes of antibody-mediated rejection (AMR) in kidney transplant patients treated with intravenous immunoglobulin (IVIG) in southern Tasmania.
Background: Accurately diagnosing and treating AMR is crucial to
preventing transplant failure and improving long term patient outcomes.
Methods: This retrospective clinical audit reviewed renal transplant patients
with AMR managed by the Royal Hobart Hospital and treated with IVIG
between 1/1/2009 and 31/12/2019 using AUDIT4 and Digital Medical
Records. AMR was diagnosed as per Banff criteria.
Results: We identified 25 patients (13 (52%) females), mean age 58 years
(range 32-74 years) diagnosed with AMR and treated with IVIG during the
study period. HLA mismatches with donor kidney were a mean of 3 MHC
class 1 and 1 MHC class 2 mismatches.
Patients received between 2 and 22 IVIG treatments at an average dose of
0.53 g/kg each, with up to 20 sessions of plasma exchange (PEX).
At 12-months post biopsy, half (46%) of the patients had reduced eGFR
(defined as >10% decrease compared to base values at biopsy) after receiving
an average of 10.2 IVIG treatments at 0.55 g/kg each and 6.5 PEX at 19 L
total volume. The other half (54%) of patients had either stable (within 10%
of base values) or improved eGFR (defined as >10% increase compared to
base values at biopsy) after receiving an average of 5.8 IVIG treatments at
0.51 g/kg each and 6.6 PEX at 21.8 L total volume. Four (16%) patients
experienced IVIG side effects including migraines and nausea.
Conclusion: Following treatment with IVIG slightly more than half of the
patients with AMR showed stabilization or improvement in renal function.
Item Details
| Item Type: | Conference Extract |
|---|---|
| Keywords: | chronic kidney disease, dialysis, end-stage kidney disease, transplant |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Clinical sciences |
| Research Field: | Nephrology and urology |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Treatment of human diseases and conditions |
| UTAS Author: | Patel, Bansari (Ms Bansari Patel) |
| UTAS Author: | Nejatian, A (Misc Ava Nejatian) |
| UTAS Author: | Skeat, L (Dr Lee Skeat) |
| UTAS Author: | Kirkland, G (Dr Geoffrey Kirkland) |
| UTAS Author: | Jose, M (Professor Matthew Jose) |
| ID Code: | 142067 |
| Year Published: | 2020 |
| Deposited By: | Medicine |
| Deposited On: | 2020-12-10 |
| Last Modified: | 2021-05-21 |
| Downloads: | 0 |
Repository Staff Only: item control page